Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered ventilator coach aims to protect lungs in ICU

NCT ID NCT07307066

Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This trial tests a real-time algorithm-driven system that gives doctors feedback on ventilator settings to protect the lungs of critically ill patients. The study will include 208 adults on breathing machines with acute respiratory distress syndrome (ARDS). The goal is to see if the system helps achieve safer ventilation targets over the first 72 hours, potentially reducing lung injury.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Real-time algorithm-driven ventilation feedback device
What this could lead to
If it works, this could help reduce lung injury from ventilators and improve outcomes for critically ill patients.
What could go wrong
This is an early-stage device trial with 208 patients, so results may not apply broadly. The device only provides feedback; it does not directly treat the underlying disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 208 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 75 years * Receiving invasive mechanical ventilation via endotracheal intubation at the time of screening * Initiation of invasive mechanical ventilation within the past 24 hours * PaO₂/FiO₂ ≤ 200 mmHg on PEEP ≥ 8 cmH₂O or, if arterial blood gas is unavailable: SpO₂/FiO₂ ≤ 235 with SpO₂ ≤ 97% * Chest imaging (chest X-ray or CT) showing bilateral pulmonary infiltrates not fully explained by pleural effusions, lobar collapse, or pulmonary nodules * Respiratory failure not fully explained by cardiac failure or fluid overload * Expected to require invasive mechanical ventilation for ≥ 72 hours after enrollment Exclusion Criteria: * Receipt of extracorporeal membrane oxygenation (ECMO) or high-frequency oscillatory ventilation at screening * Brain death or anticipated withdrawal of life-sustaining treatment within 72 hours * Pregnancy * Known neuromuscular disease affecting spontaneous respiratory effort * Prisoners or individuals unable to provide informed consent or surrogate consent * Simultaneous enrollment in another interventional ICU study * Lack of digital infrastructure for real-time ventilator waveform acquisition

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS (acute respiratory distress syndrome) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute lung injury acute respiratory distress syndrome Critical Illness respiratory failure Ventilator-Induced Lung Injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS (acute respiratory distress syndrome) Critical illness Respiratory failure Vili (ventilator-induced lung injury)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Qujing Central Hospital of Yunnan Province

    RECRUITING

    Qujing, Yunnan, 655000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.